Original Data

Bromocriptine-Induced Hyperglycemia in Nonobese Diabetic Mice: Kinetics and Mechanisms of Action

Sylvie Durant¹, Josiane Coulaud², Francoise Homo-Delarche²

Keywords: type 1 diabetes, NOD mouse, bromocriptine, insulin, glucagon, corticosterone, dopamine, L-Dopa

Abstract

The effects of bromocriptine (10 mg/kg), known to inhibit prolactin secretion and lower autoimmune processes, were studied on glucose homeostasis in non-fasted non-obese diabetic mice, a spontaneous model of type 1 diabetes. Hyperglycemia was observed 120 and 240 min after i.p. but not s.c. injection. Bromocriptine administration i.p. led to rapid and marked hyperglycemia characterized by sexual dimorphism with males having higher glycemia than females. Bromocriptine induced a rapid but transient decrease in insulinemia in males only and biphasic increases in glucagon levels and a sustained stimulatory effect on circulating corticosterone in both sexes. Bromocriptine-induced hyperglycemia involved D2-dopaminergic receptors, as demonstrated by the inhibitory effect of the D2-dopamine antagonist, metoclopramide (10 mg/kg). Simultaneous injection of bromocriptine and metoclopramide also blocked the rise in blood corticosterone. In conclusion, by inducing hyperglycemia, i.p. bromocriptine administration to prediabetic autoimmune mice may counteract its beneficial anti-immunostimulatory effects.

Fulltext: HTML , PDF (358KB)

This article has been cited by other articles:

	Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice de Leeuw van Weenen JE, Parlevliet ET, Schröder-van der Elst JP, van den Berg SA, Willems van Dijk K, Romijn JA, Pijl H Exp Diabetes Res 2011. 2011:928523
	The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B Biochem Pharmacol 2010. 79(12):1827-1836
	Leptin increases striatal dopamine D2 receptor binding in leptin-deficient obese (ob/ob) mice Pfaffly J, Michaelides M, Wang GJ, Pessin JE, Volkow ND, Thanos PK Synapse 2010. 64(7):503-510
	Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity Davis LM, Michaelides M, Cheskin LJ, Moran TH, Aja S, Watkins PA, Pei Z, Contoreggi C, McCullough K, Hope B, Wang GJ, Volkow ND, Thanos PK Neuroendocrinology 2009. 89(2):152-162